The ‘HOPE’ for primary prevention of cardiovascular disease: An Asian perspective

Abstract

Cardiovascular diseases (CVDs) are a leading cause of
morbidity and mortality. Hence, effective pharmacological
primary prevention strategies are of considerable interest.
Clinical studies of primary prevention strategies have
shown evidence of decline in cardiovascular mortality in
the western population. However, the Asian population
has not been represented well in previous Blood Pressure
(BP) and cholesterol lowering trials in primary prevention.
In view of this, the results of the recently reported Heart
Outcome Prevention Evaluation-3 (HOPE-3) trial, a
large multicenter international trial with over half the
subjects enrolled from Asian countries, is of particular
interest from the Asian perspective.